Clinical Use and Mechanisms of Infliximab Treatment on Inflammatory Bowel Disease: A Recent Update

Abstract EN

The pathogenesis and treatment of inflammatory bowel disease (IBD) have been recently advanced, while it is still challenged with high morbidity and poor prognosis.

Infliximab, a monoclonal antibody of tumor necrosis factor (TNF), has emerged as an efficient treatment with many clinical benefits such as quick disease activity reduction and IBD patient life quality improvement.

However, the biological effects of infliximab on IBD need to be elucidated.

This paper reviewed the clinical use and recently advanced biological action of infliximab on IBD.

By forming the stable complex with the soluble or the membrane form of TNF in fluid environment or on cell surface of immune cell, fibroblast, endothelium, and epithelium, infliximab quenches TNF activity and performs the important biological actions which lead to amelioration and remission of immune responses.

The mechanisms of infliximab treatment for IBD were intensively discussed.

The recent advances on two topics including predictors and side effects of infliximab treatment were also reviewed.